Article: Nicotinamide Riboside Restores Mitochondrial Function in Alpers’ Syndrome: Preclinical Findings

PrevNext
Mitochondrial Health Neurological Health Orphan Disease Preclinical

Nicotinamide Riboside Restores Mitochondrial Function in Alpers’ Syndrome: Preclinical Findings

Synopsis

Alpers' syndrome is a devastating early-onset neurodegenerative disorder caused by POLG mutations impairing mitochondrial DNA replication. Patient-derived iPSCs were used to create brain organoids and neural stem cells, which replicated the mitochondrial and neuronal defects seen in patients. Treatment with nicotinamide riboside (NR) improved mitochondrial function in these organoids, suggesting NR could be a potential therapeutic strategy for Alpers' syndrome and other mitochondrial disorders with similar mechanisms.

Journal

International Journal of Biological Sciences

Share

Read more

Diabetes

Nicotinamide Riboside and Nicotinamide Mononucleotide Restore Nerve Function in Diabetic Neuropathy: Preclinical Findings

SynopsisReduced NAD+ signaling contributes to nerve degeneration in diabetic peripheral neuropathy. Researchers tested NAD+ precursors, nicotinamide riboside and nicotinamide mononucleotide, in cul...

Read more
Clinical

Stem Cell Extracellular Vesicles Loaded with Nicotinamide Riboside, NAD+, and Resveratrol Rejuvenate Skin and Prevent Photoaging: Clinical Findings

Objectives To investigate the potential synergistic effects of loading small extracellular vesicles from adipose (fat)-derived stem cells (ASC-sEVs) with NR, NAD+, and resveratrol on photoaging an...

Read more